Eli Lilly developed the weight-loss drug Zepbound and briefly became the world’s most valuable healthcare company in 2024.
Investor enthusiasm centered on tirzepatide, the active ingredient in Zepbound and the diabetes medicine Mounjaro. Tirzepatide acts on two hormone pathways involved in blood-sugar regulation and appetite, creating strong demand and lifting expectations for Eli Lilly’s future sales.
Zepbound received approval from the U.S. Food and Drug Administration in November 2023 for chronic weight management in adults with obesity or overweight plus a related condition. Mounjaro was approved earlier for type 2 diabetes. The medicines are related but have different approved uses and brand names.
Eli Lilly was founded in Indianapolis in 1876 by Colonel Eli Lilly. Its market capitalization changes daily with its share price, and temporary rankings can differ by exchange, currency, and comparison date.